ArticleProceedings of the National Academy of Sciences of the United States of America1998
A phage display approach for rapid antibody humanization: designed combinatorial V gene libraries.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 95 citations in OpenAlex.
- Universal Baseline forbioRxiv : the preprint server for biology · 2026Article
- Development of novel canine phage display-derived neutralizing monoclonal antibody fragments against rabies virus from immunized dogs.Scientific reports · 2024Article
- Highly Specific Peptide-Mediated Cuvette-Form Localized Surface Plasmon Resonance (LSPR)-Based Fipronil Detection in Egg.Biosensors · 2022Article
- CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil.Frontiers in immunology · 2022Review
- Plant/Bacterial Virus-Based Drug Discovery, Drug Delivery, and Therapeutics.Pharmaceutics · 2019Review
- CAR T cells targeting αAdvances in cell and gene therapy · 2018Article
- The Therapeutic Antibody LM609 Selectively Inhibits Ligand Binding to Human αStructure (London, England : 1993) · 2017Article
- Article
- From rabbit antibody repertoires to rabbit monoclonal antibodies.Experimental & molecular medicine · 2017Review
- Protein and Antibody Engineering by Phage Display.Methods in enzymology · 2016Article
- Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Article
- Production and characterization of a humanized single-chain antibody against human integrin alphav beta3 protein.The Journal of biological chemistry · 2011Article
- Conversion of scFv peptide-binding specificity for crystal chaperone development.Protein engineering, design & selection : PEDS · 2011Article
- Integrin targeted therapeutics.Theranostics · 2011Article
- The first human epitope map of the alphaviral E1 and E2 proteins reveals a new E2 epitope with significant virus neutralizing activity.PLoS neglected tropical diseases · 2010Article
- Selecting and screening recombinant antibody libraries.Nature biotechnology · 2005Review
- Rational monoclonal antibody development to emerging pathogens, biothreat agents and agents of foreign animal disease: The antigen scale.Veterinary journal (London, England : 1997) · 2005Review
- Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus.Molecular immunology · 2005Article
- Using antibody catalysis to study the outcome of multiple evolutionary trials of a chemical task.Proceedings of the National Academy of Sciences of the United States of America · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The development of a new strategy for antibody humanization is described. This strategy incorporates key recognition sequences from the parental rodent antibody into a phage display-based selection strategy. The original sequences of the third complementarity-determining regions (CDRs) of heavy and light chains, HCDR3 and LCDR3, were maintained and all other sequences were replaced by human sequences selected from phage-displayed antibody libraries. This approach was applied to the humanization of mouse mAb LM609 that is directed to human integrin alphav beta3 and has potential applicability in cancer therapy as an antiangiogenic agent. We demonstrate this approach (i) provides a rapid route for antibody humanization constraining the content of original mouse sequences in the final antibodies to the most hypervariable of the CDRs; (ii) generates several humanized versions with different sequences at the same time; (iii) results in affinities as high as or higher than the affinity of the original antibody; and (iv) retains the antigen and epitope specificity of the original antibody. The production of multiple humanized variants may present advantages in the selection of antibodies that are more readily expressed on a large scale and could be important in therapeutic regimens that call for long-term treatment with antibodies in which antiidiotypic responses might be avoided by administration of alternative antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.